| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.5 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.5 |